Novel Biologics

Who We Are

Inventive People, Novel Solutions

Our power comes from our people.

We’ve been blessed with a team of experienced high-performers.
Let us introduce you to the staff that makes the Novel mission possible.


Todd Morgan is biotech/pharma career professional with 33 years’ experience in the industry. His technical experience includes bioprocess development, scale-up, commercial implementation, and design/construction of biotech/pharma processes and facilities. As a business leader he has successfully launched start-ups and lead cross-functional technical teams of engineers and scientists in various areas of business including professional service, construction management and drug/biologic development and manufacturing operations.

Todd Morgan

Co-founder & VP Business Development

Pankaj Khanna

Co-founder & President

Pankaj Khanna is a business leader and process development & scale-up expert with 15+ years of experience in the biotech industry. He has worked for many biotech companies with increasing level of responsibility. Pankaj has been involved in technology development, scale-up and commercialization of multiple products in vaccines, mABs & human plasma domain. He is also a serial entrepreneur and investor with multiple successful ventures in the field of biotechnology.
Konstantin Rodionov is seasoned professional, with over 15 years of diverse business management and operations experience. The entrepreneurial-minded Konstantin is a recognized expert in business processes, financial controls and operations management. He has worked with multiple start-up companies in diverse industries.

Konstantin Rodionov

Co-founder & VP Operations

Santhosh Kallivalappil

Co-founder & Executive Director R&D

Santhosh Kallivalappil is an expert in cell and gene therapy with more than 21 years of experience in cell & gene therapy, gene editing in vitro and in vivo models, regenerative medicine, mRNA design & synthesis, nanoparticle mediated delivery of protein and nucleic acids & molecular biology. He has extensive experience in developing and working with various animal models for cell and gene therapy.

We’re on a search for our CTO. Please contact leadership if you or someone you know is interested in joining our team.

Actively Recruiting


Scientific Board

Jeffrey C. Baker, Ph.D.

Board Advisor

Dr. Baker has received numerous awards and citations within the FDA for leadership of projects and programs on an breadth of topics and in 2018 received an FDA Honors Award for contributions to “modernizing the U.S. regulatory system for biotechnology products through sustained creative leadership and collaboration.”  In 2019 Dr. Baker was detailed to the Advanced Manufacturing National Program Office at NIST where he worked with NIST and ManufacturingUSA programs on biopharmaceutical elements of the National Strategic Plan for Manufacturing in the United States and to speed the deployment of advanced technologies into biopharmaceutical manufacturing.  He was recalled to FDA 2020 to participate in CDER responses to the global pandemic and interagency advanced manufacturing programs through the Office of the Commissioner.  He retired from the Agency in April of 2021.  He remains active in the biotech community as a Senior Fellow in the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), participating in conferences, and working with several universities as a both a lecturer and advisor on program development.

In 1994, Dr. Levine founded BioProcess Technology Consultants (BPTC), a leading consulting company that provided integrated strategic, technical, and regulatory advice on biopharmaceutical product development to a broad range of companies. He served as President, and CEO of BPTC until its merger with BDO in 2019. Over the next three years, Dr. Levine worked to fully integrate BPTC into the BDO Life Sciences advisory practice while helping to expand the group and increase revenue over 60%.

Prior to founding BPTC, Dr. Levine was Vice President of Manufacturing Operations at Repligen Corporation and previously held positions of increasing responsibility in process development and manufacturing at Genentech, Amgen, and Xoma. Dr. Levine is a frequently invited lecturer on manufacturing strategy, downstream processing, and commercialization of biotechnology products and an author of numerous, peer-reviewed publications. He holds a Ph.D. in chemistry from the University of Chicago and completed a post-doctoral fellowship at Harvard University.

Howard L. Levine, Ph.D.,

Board Advisor

Matthew Weinstock

Board Advisor

His efforts have led to technologies that have been successfully commercialized or have resulted in technology development partnerships with top-10 pharma companies and government agencies such as DARPA.  He has experience working in both start-up and growth-stage companies, having built and led a >200-person scientific organization as Chief Technology Officer.


Dr. Weinstock also has a passion for STEM education and supporting the development of the next generation of scientists and sustains this interest by developing and teaching courses through University of California, San Diego Extended Studies.


He has a PhD in Biochemistry from the University of Utah School of Medicine where his dissertation centered on the advancement of mirror-image display technologies to discover D-peptide therapeutics against emerging infectious diseases.